KIAA0101 is associated with human renal cell carcinoma proliferation and migration induced by erythropoietin

Erythropoietin (EPO) is a frequently prescribed anti-anemic drug for patients with advanced renal carcinoma. However, recent evidence from clinical studies suggested that EPO accelerated tumor progression and jeopardized the 5-year survival. Herein, we show, starting from the in silico microarray bi...

Descripción completa

Detalles Bibliográficos
Autores principales: Fan, Shengjun, Li, Xin, Tie, Lu, Pan, Yan, Li, Xuejun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4924658/
https://www.ncbi.nlm.nih.gov/pubmed/26575329
http://dx.doi.org/10.18632/oncotarget.5876

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4924658/
https://www.ncbi.nlm.nih.gov/pubmed/26575329
http://dx.doi.org/10.18632/oncotarget.5876

Ejemplares similares